Assessment of Adipocyte Transduction Using Different AAV Capsid Variants

被引:0
|
作者
Boychenko, Stanislav [1 ]
Abdullina, Alina [1 ]
Laktyushkin, Viktor S. [2 ]
Brovin, Andrew [1 ]
Egorov, Alexander D. [1 ]
机构
[1] Sirius Univ Sci & Technol, Sci Ctr Translat Med, Gene Therapy Dept, Sirius 354340, Russia
[2] Sirius Univ Sci & Technol, Resource Ctr Cell Technol, Lab Complex, Sirius 354340, Russia
基金
俄罗斯科学基金会;
关键词
adeno-associated virus; viral tropism; adipocytes; adipose tissue; anti-obesity agents; gene therapy; ADIPOSE-TISSUE; VECTORS; TARGET;
D O I
10.3390/ph17091227
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Background/Objectives: Adeno-associated viruses (AAVs) are widely used as viral vectors for gene delivery in mammalian cells. We focused on the efficacy of the transduction of AAV2/5, 2/6, 2/8 and 2/9 expressing GFP in preadipocyte cells by live imaging microscopy using IncuCyte S3 and flow cytometry. Methods: Three transduction modes in 3T3-L1 preadipocyte cells assessed: AAV transduction in 3T3-L1 preadipocyte cells, transduction with further differentiation into mature adipocyte-like cells and the transduction of differentiated 3T3-L1 adipocytes. For the in vivo study, we injected AAV2/6, AAV2/8 and AAV2/9 in adipose tissue of C57BL6 mice, and the transduction capacity of AAV2/6, along with AAV2/8 and AAV2/9 was evaluated. Results: AAV2/6 demonstrated the highest transduction efficiency in 3T3-L1 preadipocytes, as it was 1.5-2-fold more effective than AAV2/5, and AAV2/8 in the range of viral concentrations from 2 x 104 to 1.6 x 105 VG/cell. AAV2/5 and AAV2/8 showed transduction efficiencies similar to each other. The expression of GFP under the CMV promoter remained stable for up to 20 days. The induction of 3T3-L1 differentiation in three days after AAV transduction did not alter the GFP expression level, and AAV2/6 showed the best transduction efficiency. AAV2/6 demonstrated the ability to transduce mature adipocytes. These results were confirmed by in vivo studies on C57BL6 mice. AAV2/6 had the highest transducing activity on both inguinal and interscapular adipose tissue. Conclusions: Thus, AAV2/6 has demonstrated higher transduction efficacy compared to AAV2/5, AAV2/8 and AAV2/9 both in 3T3-L1 adipocytes and adipose tissue in vivo, which proves its usability along with AAV2/8 and AAV2/9 for gene delivery to adipocytes.
引用
收藏
页数:16
相关论文
共 50 条
  • [41] Massively Parallel Screening of Barcoded AAV Capsid Variants for Neutralizing Antibody Reactivity
    Rapti, Kleopatra
    Kraemer, Chiara
    Meng, Ning
    Grimm, Dirk
    MOLECULAR THERAPY, 2024, 32 (04) : 465 - 466
  • [42] Massively parallel screening of barcoded AAV capsid variants for neutralizing antibody reactivity
    Rapti, K.
    Kraemer, C.
    Grimm, D.
    HUMAN GENE THERAPY, 2024, 35 (3-4) : A71 - A71
  • [43] Identification of a myotropic AAV by massively parallel in vivo evaluation of barcoded capsid variants
    Jonas Weinmann
    Sabrina Weis
    Josefine Sippel
    Warut Tulalamba
    Anca Remes
    Jihad El Andari
    Anne-Kathrin Herrmann
    Quang H. Pham
    Christopher Borowski
    Susanne Hille
    Tanja Schönberger
    Norbert Frey
    Martin Lenter
    Thierry VandenDriessche
    Oliver J. Müller
    Marinee K. Chuah
    Thorsten Lamla
    Dirk Grimm
    Nature Communications, 11
  • [44] Quantifying transduction efficiencies of unmodified and tyrosine capsid mutant AAV vectors in vitro using two ocular cell lines
    Ryals, Renee C.
    Boye, Sanford L.
    Dinculescu, Astra
    Hauswirth, William W.
    Boye, Shannon E.
    MOLECULAR VISION, 2011, 17 (124): : 1090 - 1102
  • [45] Engineered AAV13 variants with enhanced transduction and confined spread
    Luo, Neng-Song
    Cai, Yu-Xiang
    Han, Zeng-Peng
    Sui, Xiao-Kai
    Yuan, Wen-Jia
    Zhang, Zi-Lian
    Guo, Hao-Dong
    Wang, Jie
    Lin, Kun-Zhang
    Xu, Fu-Qiang
    ZOOLOGICAL RESEARCH, 2024, 45 (04) : 781 - 790
  • [46] Modification of AAV9 capsid at different positions affects differently to AAV infectivity in culture
    Milagros, S.
    Ramirez, P.
    Guembe, M.
    Uribarri, A.
    Carte, B.
    Mauleon, I.
    Mendez, M.
    Aldabe, R.
    HUMAN GENE THERAPY, 2024, 35 (3-4) : A87 - A87
  • [47] RNA-Driven Evolution of AAV Capsid Libraries Identifies Variants with High Transduction Efficiency in Non-Human Primate Central Nervous System
    Nonnenmacher, Mathieu
    Li, Shaoyong
    Wang, Wei
    Child, Matthew A.
    Ren, Amy Z.
    Tyson, Katherine
    Pande, Nilesh
    Lu, Xiaodong
    Li, Jiangyu
    Ren, Xiao-Qin
    Shang, Jianyu
    Hefferan, Michael
    Hou, Jay
    Khwaja, Omar
    MOLECULAR THERAPY, 2021, 29 (04) : 25 - 26
  • [48] Intravitreal injection of a rationally designed AAV capsid library in non-human primate identifies variants with enhanced retinal transduction and neutralizing antibody evasion
    Kellish, Patrick C.
    Marsic, Damien
    Crosson, Sean M.
    Choudhury, Shreyasi
    Scalabrino, Miranda L.
    Strang, Christianne E.
    Hill, Julie
    McCullough, K. Tyler
    Peterson, James J.
    Fajardo, Diego
    Gupte, Siddhant
    Makal, Victoria
    Kondratov, Oleksandr
    Kondratova, Liudmyla
    Iyer, Siva
    Witherspoon, C. Douglas
    Gamlin, Paul D.
    Zolotukhin, Sergei
    Boye, Sanford L.
    Boye, Shannon E.
    MOLECULAR THERAPY, 2023, 31 (12) : 3441 - 3456
  • [49] Deamidation of Adeno-Associated Virus Capsid Impacts Transduction Activity in AAV9
    Meggersee, Rosemary L.
    Sims, Joshua J.
    Lian, Sharon
    Turner, Kevin B.
    Hoff, Henry B.
    Wilson, James M.
    MOLECULAR THERAPY, 2020, 28 (04) : 14 - 14
  • [50] Quantitative Analysis Reveals the Impact of the Empty to Full Capsid Ratio on AAV Vector Transduction In Vivo
    Wu, Shiyong
    Yamada, Kentaro
    Miller, Lohra M.
    Li, Xin
    Gonzalez, Miguel
    Arisa, Sreevani
    Tian, Jiahe
    Jarrold, Martin F.
    Herzog, Roland W.
    Xiao, Weidong
    Draper, Benjamin E.
    Zhang, Junping
    MOLECULAR THERAPY, 2024, 32 (04) : 720 - 720